Suppr超能文献

恶性肿瘤患者自体造血干细胞移植后的造血重建:一项多中心回顾性研究。

Haemopoietic reconstitution after autologous blood stem cell transplantation in patients with malignancies: a multicentre retrospective study.

作者信息

Pierelli L, Iacone A, Quaglietta A M, Nicolucci A, Menichella G, Benedetti Panici P, D'Antonio D, De Laurenzi A, De Rosa L, Fioritoni G

机构信息

Servizio di Ematologia ed Emotransfusione, Universitá Cattolica del Sacro Cuore, Roma, Italy.

出版信息

Br J Haematol. 1994 Jan;86(1):70-5. doi: 10.1111/j.1365-2141.1994.tb03254.x.

Abstract

A retrospective study was undertaken to evaluate the efficacy of autologous blood stem cell transplantation (ABSCT) in terms of haemopoietic reconstitution after ablative chemotherapy or chemo-radiotherapy. 55 patients with malignancies, observed in four Italian institutions from January 1987 to June 1991, were eligible for evaluation. This series included 19 non-Hodgkin's lymphoma, 11 multiple myeloma, nine ovarian cancer, seven Hodgkin's disease, seven non-lymphocytic leukaemia, one acute lymphoblastic leukaemia, one neuroblastoma. 522 PBSC collections were performed on 55 patients. Following ABSCT, the rate of engraftment was positively related to the dose of CFU-GM infused and negatively to the presence of bone marrow involvement at conditioning. 48 patients out of 55 transplanted (87%) had rapid, complete and sustained engraftment. Three patients (5%) died of transplant-related complications. Considering that 60% of the patients in this series were in partial remission or in progressive disease at the time of ABSCT, we conclude that ABSCT is a safe approach for the use of ablative conditioning therapy in patients with a wide scope of malignancies, provided that a large number of CFU-GM have been collected after mobilizing treatment.

摘要

进行了一项回顾性研究,以评估自体血干细胞移植(ABSCT)在大剂量化疗或放化疗后造血重建方面的疗效。1987年1月至1991年6月在意大利四个机构观察的55例恶性肿瘤患者符合评估条件。该系列包括19例非霍奇金淋巴瘤、11例多发性骨髓瘤、9例卵巢癌、7例霍奇金病、7例非淋巴细胞白血病、1例急性淋巴细胞白血病、1例神经母细胞瘤。对55例患者进行了522次外周血干细胞采集。ABSCT后,植入率与输注的CFU-GM剂量呈正相关,与预处理时骨髓受累情况呈负相关。55例移植患者中有48例(87%)实现了快速、完全且持续的植入。3例患者(5%)死于移植相关并发症。鉴于该系列中60%的患者在进行ABSCT时处于部分缓解或疾病进展期,我们得出结论,对于广泛范围的恶性肿瘤患者,只要在动员治疗后采集到大量CFU-GM,ABSCT是一种使用大剂量预处理疗法的安全方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验